Oncolytics Biotech to Pursue Phase II/III Head and Neck Cancer Trial
Posted on: Wednesday, 5 November 2008, 12:00 CST
Oncolytics Biotech has made a decision to pursue a pivotal Phase II/III randomized trial using the combination of Reolysin with paclitaxel/carboplatin in refractory patients with head and neck cancers.
The decision was made following a review of results by the company's board of directors from the company's ongoing UK Phase I and Phase II combination Reolysin and paclitaxel/carboplatin clinical trials.
Oncolytics is currently convening a group of experts in Europe and the US to design a protocol for the Phase II/III trial, which will then be submitted to the FDA, and the European Medicines Agency (EMEA) for review. Following FDA and EMEA review, Oncolytics expects to file for approval for this trial early in 2009.
Brad Thompson, president and CEO of Oncolytics, said: "Approximately eight out of nine head and neck patients reported on to date from the Phase I and Phase II studies had either a partial response or stabilization of disease. This response rate exceeds that of the current standard of care for this patient group, and more than warrants proceeding to a pivotal program."
Source: Datamonitor
Related Articles
- First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
- Final Results From Phase 2 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Published in the American Cancer Society's Journal Cancer
- FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
- Lpath Gets FDA Nod to Initiate Phase I Cancer Trial
- Gentium Announces the Data Safety Monitoring Board Review of the Phase III Trial of Defibrotide to Treat Patients With Severe Veno-Occlusive Disease
- Delcath Systems Receives National Cancer Institute Approval to Expand Phase III Trial to Multiple Centers
- FluoroPharma Announces Commencement of Phase I Clinical Trials for CardioPET, a Novel PET Imaging Agent
- VaxGen Publishes Results of Phase I Clinical Trial of Anthrax Vaccine Candidate
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
- Genmab A/S and Medarex Announce Positive Safety and Efficacy Data in Phase I/II Trial With HuMax-Inflam/MDX-018
 |
 |
User Comments (0)
RSS Feeds